Cytori Therapeutics (NASDAQ:CYTX) has received approval from the Health Sciences Authority (HSA) in Singapore for the Celution® System for autologous re-implantation or re-infusion of a patient’s own adipose-derived regenerative cells (ADRCs). The Celution® System enables access to a patient’s own ADRCs at the point-of-care for a range of injuries and conditions.
“Celution® System approval and claims in Singapore complements our existing Asia-Pacific approvals by strengthening market access in the region and reinforcing our global regulatory strategy. We anticipate seeing a relevant impact on sales in 2014 as a result of the approval in Singapore, combined with recent approvals and registrations in Australia, New Zealand and in Japan,” said Seijiro Shirahama, President of Asia-Pacific for Cytori. “We will continue to pursue new regulatory approvals in large markets and strategic countries in Asia as well as continue to expand existing claims for the Celution® System in the more than 40 countries where we already have approval.”
Asia-Pacific has been and continues to be a key region for Cytori, supported by a growing number of regulatory approvals and patents issued. In 2007 and 2008, Cytori received patents in Singapore covering the Celution® System and for vascular conditions relating to the use of ADRCs to restore blood flow.
Singapore represents a major medical market and is a leader in medical innovation and research, being ranked fourth in global healthcare infrastructure in the IMD World Competitiveness Yearbook in 2010. Singapore has committed more than $12 billion in continued support of research, innovation and enterprise activities between 2011 and 2015, $2.9 billion of which is dedicated to the biomedical space.About Adipose Tissue & ADRCs Adipose tissue is considered the richest source of regenerative cells in the body. These cells are comprised of a heterogeneous population of cells which are collectively referred to as ADRCs. The heterogeneous nature of ADRCs are believed to contribute to the healing process via multiple mechanisms, which include cell-to-cell signaling, supporting improved blood flow and regulation of the inflammatory response.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts